Генетические основы этиологической гетерогенности злокачественных новообразований
Диссертация
Проблема своевременного выявления РЩЖ, МК, ПМЗО заключается не только в бессимптомном развитии новообразования, но и в отсутствии надежных маркеров, способствующих их раннему выявлению. Наряду с этим, первично-множественные опухоли представляет собой особую диагностическую проблему. Изучения прицельно направленные на выявление специфических признаков, которые могли бы у пациентов увеличивать риск… Читать ещё >
Список литературы
- Бабаянц P.C., Лоншаков ГО.И.// Расстройства пигментации кожи.- М.-1978.-143С.
- Белев Н.Ф., Самотыя Е. Е., Пикхут П. М., Кудина E.H., Трубников В. И., Казубская Т. П., Гарькавцева Р. Ф. Сегрегационнй и генетико-дисперсион-ный анализ предрасположенности к аденомам и раку толстой кишки.// Генетика. 1999, Т.35, № 4, С.524−529.
- Бочков Н.П. Клиническая генетика 2001г. Москва. ГЭОТАР-Мед, 447С.
- Брага Э.А., Киселев Л. Л., Забаровский Е. Р. 2004.От идентификации геномных полиморфизмов к диагностическим и прогностическим маркерам эпителиальных опухолей человека.//Молекуляр. Биология. 2004, Т.38, С.179−190.
- Гарькавцева Р.Ф., Ситникова Т. С., Казубская Т. П. и др. Клинико-генети-ческие аспекты меланомы кожи.1. Распространенность, семейное изучение, генетическая гетерогенность.// Генетика. 1995, Т.31, № 11, С. 15 571 561.
- Гарькавцева Р, Ф, Нефедов М. Д., Летягин В. П., Самгина A.A. Наследственные аспекты и гетерогенность рака молочной железы.//Советская медицина. 1987, № 9, С. 92−96.
- Гинтер Е.К. Медицинская генетика. М., Медицина, 2001,528С.
- Ильин Ф.Ф., Румянцев П. О., Медведев В. С соав.//Проблемы эндокринологии. 2003, № 5, С. 45−48.
- Имянитов E.H., Хансон К. П. //Молекулярная онкология: клинические аспекты.//Санкт-Петербург. 2007, 211С.
- Казубская Т.П., Козлова В. М., Мусатов В. К. с соав. Идентификация наследственных вариантов меланомы кожи // Генетика. 2004, Т.40, № 1,1. С.88−95.
- Корчагина, Е.Л., Белев Н. Ф., Казубская Т. П., с соав. Клинико-генети-ческие аспекты рака толстой кишки и идентификация его наследственных форм // Колопроктология. 2008, № 2, С. 19−24.
- Логинов В, Базов И., Ходырев Д., Пронина М. Казубская Т., с соав. Районы потенциальных генов-супресеоров эпителиальных опухолей почки, молочной железы и яичников на хромосоме 3 человека. //Генетика. Т.44, С.209−214.
- Нефедов М.Д., Гарькавцева Р. Ф., Трубников В. И. Генетика рака молочной железы. Генетико-дисперсионный анализ и генетическая гетерогенность.// Генетика. 1988, Т.24, № 8, С. 1456−1461.
- Ситникова Т.С. Медико-генетические аспекты меланомы кожи.// Автореферат диссертации кан. мед.наук. М. Москва. 1988, С. 25.
- Статистика злокачественных новообразований в России и странах СНГ в 2006 г. под ред. М. И. Давыдова, Е.М.Аксель" Вестник РОНЦ им. Н.Н.Бло-хинаРАМН. 2008, Т. 19, приложение 1.
- Трубников В.И. Корреляции между родственниками из серии: генетико-математические методы, алгоритмы и программы // Методические разработки. Москва, 1998, — 28С.
- Ходырев Д.С., Логинов В. И., Пронина И. В., КазубскаяТ.П., Гарькавцева Р. Ф., Брага Э. А. Метилирование промоторной области гена RAR-beta2 в опухолях почки, молочной железы, яичников// Генетика человека. 2008, Т.44, № 8, С. 1−7.
- Эндокринология под редакцией Н. Лавина, изд. «Практика».- г. Москва.-1999 г.- 1128 С.
- Шимке Р. Генетика и рак человека. Москва, 1981,183 С.
- Aarnio М, Sankila R, Pukkala Е, et al: Cancer risk in mutation carriers of DNA-mismatch-repair genes.// Int J Cancer 1999, V.81, P.214−218.
- Angeloni D. Molecular analysis of deletions in human chromosome 3p21 and the role of resident cancer genes in disease // Brief. Funct. Genomic Prote-omic. 2007, V.6, № 1,P. 19−39.
- Annessi G, Cattaruzza MS, Abeni D et al. Correlation between clinical atypia and histologic dysplasia in acquired melanocytic nevi.//J Am Acad Dermatol. 1994, V.102, P.695−699.
- Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev. 2005, V.16 № 4−5, P.441−467.
- Asai N, Iwashita T, Matsuyama M, Takahashi M. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations.//Mol Cell Biol.1995, V.15, № 3, P.1613−1619.
- Bale SJ, Dracopoli NC, Tucker MA, Clark WH, Fraser MC, et al. Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome lp //N Engl J Med. 1989, V.320.1367−1372.
- Ball D. W, Baylin S.B., DeBustos A. CV/Werner&Ingbar's the Thyroid: a Fundamental and Clinical Text. Philadelphia. 2000, P.930−943.
- Ball DW. Medullary thyroid cancer, therapeutic targets and molecular markers.// Curr Opin Oncol. 2007, V.19, № 1, P. 18−23.
- Bataille V, Bishop JA, Sasieni P et al. Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: a case-control study.// Br J Cancer 1996, V.73,P. 1605−11.
- Begg CB, Hummer AJ, Mujumdar U, et al. A design for cancer case-control studies using only incident cases: experience with the GEM study of melanoma. Int J Epidemiol 2006, V.5,P.756−64.
- Bergfeldt K, Einhorn S, Rosendahl I, Hall P. Increased risk of second primary malignancies in patients with gynecological cancer. A Swedish record-linkage study. Acta Oncol. 1995, V.34, P. 771−777.
- Bergman W, Watson P, de Jong J, Lynch HT, Fusaro RM. Systemic cancer and the FAMMM syndrome //Br J Cancer. 1990, V.61, № 6, P.932−936.
- Bevan S, Pal T, Greenberg CR, Green H, et al. A comprehensive analysis of MNG1, TCOl, fPTC, PTEN, TSHR and TRKA in familial nonmedullary thyroid cancer: confirmation of linkage to TCOl.// J Clin Endocrinol Metab. 2001, V.86, P.3701−3704.
- Birindelli S, Tragni G, Bartoli C, et al. Detection of microsatellite alterations in the spectrum of melanocytic nevi in patients with or without individual or family history of melanoma. Hint J Cancer. 2000, V.86, P.255−61.
- Biscolla RP, Ugolini C, Sculli M, et al. Medullary and papillary tumors are frequently associated in the same thyroid gland without evidence of reciprocal influence in their biologic behavior.// Thyroid. 2004, № 11, P.946−52.
- Block MA, Jackson CE, Greenawald KA, Yott JB, Tashjian AH. Clinical characteristics distinguishing hereditary from sporadic medullary thyroid carcinoma. Treatment implications.//Arch Surg. 1980, V. l 15, № 2, P.142−148.
- Bolino A., Schuffenecker I., Luo Y., Seri M., Silengo M., Tocco T., Charbrier G., et al. RET mutation in exons 13 and 14 of FMTC patients. //Oncogene. 1995, V.10, P.509−513.
- Bonis PA, Trikalinos TA, Chung M, Chew P, Ip S, DeVine DA, Lau J. Hereditary nonpolyposis colorectal cancer: diagnostic strategies and their implications.//Evid Rep Technol Assess (Full Rep). 2007, V.150, P. 1−180.
- Borg A. Sandberg T., Nilsson K., Johannsson O., et al. Frequency of Multiple Melanomas and Breast and Pancreas Carcinomas in CDKN2A MutationPositive Melanoma Families //Journal of the National Cancer Institute.2000, Y.92, No.15, P.1260−1266.
- Bos JL. Ras oncogenes in human cancer: a review.//Cancer Res. 1989, V.49, P.4682−4689.
- Brandi ML, Gagel RF, Angeli A, Bilezikian JP, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2.// J Clin Endocrinol Metab.2001,V.86, № 12, P.5658−5671.
- Burgess JR, Duffield A, Wilkinson SJ, Ware R, Greenaway TM, Percival J, Hoffman L Two families with an autosomal dominant inheritance pattern for papillary carcinoma of the thyroid.// J Clin Endocrinol Metab. 1997.V.82,1. P.345−348.
- Butter A., Gagne J., Al-Jazaeri A., Emran M.A., Deal C., at al. Prophylactic thyroidectomy in pediatric carriers of multiple endocrine neoplasia type 2A or familial medullary thyroid carcinoma: mutation in C620 is associated with
- Hirschprungs disease. // J. Pediatr. Surg. 2007, V.42, № 1, P. 203−206.
- Canchola A., Horn-Ross P., PurdieD. Risk of Second Primary Malignancies in Women with Papillary Thyroid Cancer American.//Journal of Epidemiology 2006, V. 163, № 6, P. 521−527.
- Canzian F, Amati P, Harach R, Kraimps J-L, Lesueur F, Barbier J, Levillain P, Romeo G, Bonneau D. A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19pl3.2.// Am J Hum Genet. 1998, V.63, P.1743—1748.
- Carney JA, Gordon H, Carpenter PC, Carney J. A, Carpenter P. C, Shenoy B. V, Go V.L. //The complex of myxomas, spotty pigmentation, and endocrine overactivity. //Medicine (Baltimore). 1985, V.64, № 4, P.270−283.
- Cetta F, Pelizzo MR, Curia MC, Barbarisi A Genetics and clinicopathological findings in thyroid carcinomas associated with familial adenomatous polyposis. //Am J Pathol. 1999, V. l 55, № 1, P.7−9.
- Chaudru V, Chompret A, Bressac-de Paillerets B, et al. Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families.// J Natl Cancer Inst., 2004, V.96, P.785−795.
- Chen S, Iversen ES, Friebel T, Finkelstein D, Weber BL, et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol. 2006, V.24, P.863−871.
- Chun Y, Lindor N., Smyrk T. et al. Germline E-cadherin gene mutations: Is prophylactic total gastrectomy indicated? // Cancer, 2001, V.92 P. 181−187.
- Clark S.J., Harrison J., Paul C.L., Frommer M. High sensitivity mapping of methylated cytosines. //Nucl. Acids Res. 1994, V.22, P.2990−2997.
- Clark WH Jr, Elder DE, Guerry DT, et al. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma.//Hum Pathol. 1984, V.15, P. l 147−1165.
- Clark WH Jr, Reimer RR, Greene M, Ainsworth AM, Mastrangelo MJ. Origin of familial malignant melanomas from heritable melanocytic lesions: the B-Kmole syndrome. // Arch Dermatol. 1978, V. l 14, P.723−728.
- Colman SD, Williams CA, Wallace MR. Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene.// Nat Genet. 1995, V. l l,№l, P.90−92.
- Courseaux A., Grosgeorge J., Gaudray P. et al. // European Consortium on MEN 1: Definition of the minimal MEN1 candidate area based on a 5-Mb integrated map of proximal llql3 Genomics. 1996, V.37, P.354−365.
- Crutcher WA, Cohen PJ. Dysplastic nevi and malignant melanoma. //Am Fam Physician. 1990, V.42 V.42, № 2, P.372−85.
- Czerninski R, Krichevsky S, Ashhab Y, Gazit D, Patel V, Ben-Yehuda D. Promoter hypermethylation of mismatch repair genes, hMLHl and hMSH2 in oral squamous cell carcinoma //Oral Dis. 2009, V.15, № 3, P.206−213.
- Dammann R., Schagdarsurengin U., Seidel C., Strunnikova M., Rastetter M., Baier K., Pfeifer G.P. The tumor suppressor RASSF1A in human carcinogenesis: an update.//Histol Histopathol. 2005, V.20, №.2, P.645−663.
- Dammann R., Li C., Yoon J.H., Chin P.L., Bates S. and Pfeifer G.P. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. //Nat Genet. 2000, V.25, P.315−319.
- Dong C, Plemminki K. Second primary neoplasms among 53 159 haematolym-phoproliferative malignancy patients in Sweden, 1958−1996: a search for common mechanisms.//Br J Cancer. 2001, V.85, № 7, P.997−1005.
- Dreijerink K., Braga E., Kuzmin I., Geil L., et al. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis .//ProcNatl. Acad. Sci. 2001, V.98, P.7504−7509.
- Drosten M, Putzer BM. Mechanisms of Disease, cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy.//Nat Clin
- Pract Oncol. 2006, V.3, № 10, P.564−574.
- Duffy MJ, Napieralski R, Martens JW, Span PN, et al. Methylated genes as new cancer biomarkers. Eur J Cancer. 2009, V.45, № 3, P.335−46.
- Dunn JM, Farndon JR. Medullary thyroid carcinoma.//Br J Surg. 1993, V.80, № 1, P.6−9.
- Easton DF, Steele L, Fields P, Ormistin W, Averill D, Daly PA, et al. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13ql2−13. //Am J Hum Genet 1997, V.61, P. 120−125.
- Eng C.// Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet. 2000, V.37, P.828−830.
- Eng C, Parsons R. Cowden syndrome. In: Vogelstein B, Kinzler KW, eds. The genetic basis of human cancer.- New York: McGraw Hill. 1998, P.519−526.
- Fante R., Roncucci L., Di Gregorio C, Tamassia MG et al. // Frequency and clinical features of multiple tumors of large bowel in the general population and in patients with hereditary colorectal carcinoma Cancer. 1996, V.77, № 10, P.2013−21.
- Ferrone CR, Ben Porat L, Panageas KS, Berwick M, Halpern AC, Patel A, Coit DG. Clinicopathological features af and risk faktors for multiple primaiy melanomas.// JAMA. 2005, V.294, № 13, P.647−54.
- FitzGerald, M.G., D.P. Harkin, S. Silva-Arrieta, D. J, et al. Prevalence of germ -line mutations in pi6, pl9ARF, and CDK4 in familial melanoma: Analysis of a clinic-based population.//Proc. Natl. Acad. Sci. 1996, V.93, P.8541−8545.
- Ford D, Easton DF, Bishop DT, Narod SA, Goldar DE. Risk of cancer in BRCA1-mutation carriers. Lancet. 1994, № 343, P.692−695.
- Fountain JW, Bale SJ, Housman DE, Dracopoli NC. Genetics of melanoma. //Cancer Surv. 1990, V.9, P.645−71.
- Friend SH, Bernards R, Rogelj S, Weinberg RA, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarco-ma.//Nature. 1986, V.323, P.643−6.
- Gagel R.F., Tashjian A.H., Cummings T., et al., The clinical outcome of prospective screening for multiple endocrine neoplasia type 2 A. // N Engl. J of Med.1988, V. 318, P.478−480.
- Gallino G, Belli F, Tragni G, Ferro F, et al. Association between cutaneous melanoma and neurofibromatosis type 1: analysis of three clinical cases and review of the literature.//Tumori. 2000, V.86, № 1, P.70−4
- Geary J, Sasieni P, Houlston R, Izatt L, et al. Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). //Fam Cancer. 2008, V.7, № 2, P. 163−7.
- Gibbs P, Brady BM, Robinson WA The genes and genetics of malignant melanoma.//.! Cutan Med Surg. 2002, V.6, № 3, P.229−235.
- Gayther SA, de Foy KA, Harrington P, Pharoah P, et al. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer.//Cancer Res. 2000, V.60, P.4513−8.
- Gilbert F, Potluri VR, Short MP, Kau CL, Lalatta F. Retinoblastoma, chromosome abnormalities and oncogene expression. // Ophthalmic Paediatr Genet. 1987, V.8, № 1, P.3−10.
- Giles G., Staples M., McCredie M., Coates M. Multiple primary melanomas: an analysis cancer registry data from Victoria and New South Wales. //Melanoma Res.1995, V.5, P.433−438.
- Gillanders E, Hank Juo SH, Holland EA, et al. Localization of a novel melanoma susceptibility locus to Ip22.//Am J Hum Genet. 2003- V.73, P.301−313.
- Gimm O, Attie-Bitach, Tees JA, et al. //Expression of the PTEN tumour suppressor protein during human development. //Hum Mol Genet. 2000, V.9,1. P.1633−39.
- Giunti L, Bernini G, Forni M, et al. Clonality analysis of pediatric multiple tumors: two case reports and laboratory investigation. //J Pediatr ITematol Oncol. 2006, V.28, № 4, P.241−248.
- Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands.// J Natl Cancer Inst. 1994, V.86, P. 1600−1608.
- Goldstein AM, Dracopoli NC, Ho EC, Fraser MC, et al. Further evidence for a locus for cutaneous malignant melanoma-dysplastic nevus (CMM/ DN) on chromosome lp, and evidence for genetic heterogeneity .//Am J Hum Genet 1993, V.52, № 3, P.537−550.
- Goldstein AM, Fraser MC, Clark WHJ, Tucker MA. Age at diagnosis and transmission of invasive melanoma in 23 families with cutaneous malignant melanoma/dysplastic nevi. //J Natl Cancer Inst. 1994. V.86, P.1385−1390.
- Goldstein AM, Goldin LR, Dracopoli NC, Clark WH, Tucker MA: Two-locus linkage analysis of cutaneous malignant melanoma/dysplastic nevi.//Am J Hum Genet. 1996, V.58, P.1050−1056.
- Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer Statistics. //Cancer J Clin. 2000, V.50, P.7−33.
- Greene MH, Clark WH Jr, Tucker MA, Kraemer KH, Elder DE, Fraser MC. High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. //Ann Intern Med. 1985/V.102, № 4,P.458−65.
- Greene MH, Fraumeni JF Jr. The hereditary variant of malignant melanoma. In: Clark WH Jr, Goldman LI, Mastrangelo MJ, eds. Human Malignant Mela-noma.//New York, NY: Grune & Stratton Inc- 1979, P. 139−166.
- Grossman R.F., Ozaki O, Ito K, Kobayashi K, Suzuki A, Manabe Y, Hosoda Y. Familial occurrence of differentiated, nonmedullary thyroid carcinoma. //World J Surg. 1988, V.12, P.565−571.
- Grover S, Syngal S. Genetic testing in gastroenterology: Lynch syndrome. Best Pract Res Clin Gastroenterol. 2009, V.23, № 2, P. 185−96.
- Guldberg P, thor Straten P, Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. //Cancer Res. 1997, V.57, № 17, P.3660−3.
- Ha PK, Califano JA. The molecular biology of mucosal field cancerization of the head and neck. //Cnt Rev Oral Biol Med 2003, V.14, P.363−369.
- Hadley D W, Jenkins JF- Dimond E, Nakahara K, de Carvalho M, Kirsch I, Palmer CG. Genetic Counseling and Testing in Families With Hereditary
- Nonpolyposis Colorectal Cancer//Arch Intern Med. 2003, V.163,P.573−582.
- Hafner C, Knuechel R, Steehr R, Hartman A. Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies. //Int J Cancer. 2002, V.101,P.l-6.
- Halpem A, Holly EA et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. //JAMA. 1997, V.277, P. 1439−1444.
- Halpern AC, Guerry D IV, Elder DE et al. Dysplastic nevi as risk markers of sporadic (nonfamilial) melanoma. A case-control study.//Arch Dermatol. 1991, V.127, P.995−9.
- Harper, J.W. and S.J. Elledge. Cdk inhibitors in development and cancer. //Curr. Opin. Genet. Dev. 1996, V.6, P.56−64.
- Hashemi J., Platz A., IJeno T., Stierner U., Ringborg U., Hansson J. //CDKN2 Germ-line Mutations in Individuals with Multiple Cutaneus Melanoma. //Cancer Res. 2000, V.60, № 24, P.6864−7
- Hemminki D.C. Multiple primary cancers of the colon, breast and skin (melanoma) as models for polygenic cancers.//Cancer. 2001, V.15, P.883−887.
- Hemminki K., Eng C., Chen B. // Familial risks for Nemedullary Thyroid Cancer. //J of Clin. Endocrin. and Metabolism. 2005, V.90, № 10, P. 5753−57.
- Hemminki K, Dong C Familial relationships n thyroid cancer by histolopa-thological type.// Int J Cancer. 2000, V.85, P.201−205.
- Hemminki K, Dong C. Cancer in husbands of cervical cancer patients. I I Epidemiology 2000, V. l 1, P.347−9.
- Hemminki K, Dong C. Familial relationships in squamous cell carcinoma of the skin. //Epidemiology. 2000, V. l 1, P. 309−314.
- Hemminki K, Dong C. Subsequent cancers after in situ and invasive squamous cell carcinoma of the skin.// Arch Dermatol. 2000, V.136, № 5, P.647−51.
- Hemminki K, Li X. Cancer risks in Nordic immigrants and their offspring in Sweden Eur J Cancer. 2002, V.8, № 18, P.2428−34.
- Hemminki K, Li X. Familial and second primary pancreatic cancers: a nationwide epidemiologic study from Sweden.//Int J Cancer. 2003, V.103, № 4, P.525−30.
- Hofstra RM, Landsvater RM, Ceccherini I, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. //Nature. 1994, V.367, № 6461,P.375−6.
- Holly EA, Kelly JW, Shpall SN, Chiu SH. Number of melanocytic nevi as a major risk factor for malignant melanoma.//J Am Acad Dermatol. 1987, V.17, P.459−68.
- Howe HL, Wu X, Ries LA, Cokkinides V, Ahmed F, et al. Annual report to the nation on the status of cancer, 1975−2003, featuring cancer among U.S. Hispanic/Latino populations.// Cancer. 2006, V.107, № 8, P.1711−42.
- Huang SC, Koch CA, Vortmeyer AO, Pack SD, et al. Duplication of the mutant RET allele in trisomy 10 or loss of the wild-type allele in multiple endocrine neoplasia type 2-associated pheochromocytoma. //Cancer Res. 2000, V.60, P.6223−6226.
- Hussein MR, Sun M, Tuthill RJ, et al. Comprehensive analysis of 112 melanocytic skin lesions demonstrates microsatellite instability in melanomas and dysplastic nevi, but not in benign nevi. //J Cutan Pathol. 2001, V.28, P.343−350.
- Hussein MR, Wood GS. hMLFIl and hMSH2 gene mutations are present in radial growth-phase cutaneous malignant melanoma cell lines and can be induced further by ultraviolet-B irradiation.//Exp Dermatol. 2003, V.872, № 5, P.32−42.
- Hussein MR, Wood GS. Molecular aspects of melanocytic dysplastic nevi // J Mol Diagn.2002, V.4, № 2, P.71−80.
- Hussussian, C.J., Struewing J. P, Goldstein A.M., et al. Germline pi6 mutations in familial melanoma. //Nature Genet. 1994, V.8, P.15−21.
- Hwang SJ, Cheng LS, Lozano G, Amos CI, Gu X, Strong LC. Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Hum Genet.2003,V.113, P.38−243.
- Ikeda. I, Ishizaka Y., Tahira T. et al. Specific expression of the ret proto-oncogene in human neuroblastoma cell lines. // Oncogene. 1990.V.5. № 9. P.1291−1296.
- Imyanitov EN, Suspitsin EN, Grigoriev MY, et al. Concordance of allelic imbalance profiles in synchronous and metachronous bilateral breast carcinomas. //Int J Cancer. 2002, V.100, P. 557−64.
- Indsto JO, Cachia AR, Kefford RF, et al. X inactivation, DNA deletion, and mierosatellite instability in common acquired melanocytic nevi.//Clin Cancer Res .2001,V.7, P.4054−9.
- Inskip P.D. Multiple primary tumors involving cancer and central nervous system as the first or subsequent cancer.//Cancer. 2003, V.98, P.562−569.
- Ishizaka Y, Itoh F, Tahira T, Ikeda I, Sugimura T, Tucker J, Fertitta A, Carrano AV, Nagao M. Human ret proto-oncogene mapped to chromosome 1 Oql 1.2.//Oncogene. 1989, V.4, P. 12, P. 1519−21.
- Ivanova T., Petrenko A., Gritsko T., et al. Methylation and silencing of the retinoic acid receptor-(32 gene in cervical cancer. BMC Cancer. 2002, V.2,P. 411.
- Iwashita T., Asai N., Nurakami H. et al. Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation.// Oncogene. 1996, V.12, P.481−487.
- Janschek E, Kandioler-Eckersberger D, Ludwig C, et al. Contralateral breast cancer: molecular differentiation between metastasis and second primary cancer. Breast Cancer Res Treat 2001, V.67, P. 1−8.
- Jo WS, Chung DC. Genetics of hereditary colorectal cancer.//Semin Oncol. 2005, V.32 № 1, P.11−23.
- Kahraman T., de Groot J W, Rouwe C, Hofstra RM, Links T.P., et al. Acceptable age for prophylactic surgery in children with multiple endocrine neoplasia type 2a. //Eur J Surg. Oncol.- 2003, V.29, № 4, P.331−335.
- Kaldor J. Second cancer following chemotherapy and radiotherapy. An epidemiological perspective.//Acta Oncol 1990, V.29, P.647−55.
- Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, et al. A cell cycle regulator potentially involved in genesis of many tumor types.// Science 1994, V.264, P.436−440.
- Kamb A. Cyclin-dependent kinase inhibitors and human cancer.// Curr Top Microbiol Immunol. 1998, V.227, P.139−148.
- Kamb A., D. Shattuck-Eidens, R. Eeles, Q. et al. Analysis of the pi6 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. //Nature Genet. 1994, V.8, P.23−26.
- Kamijo T, Weber JD, Zambetti G, et al. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. //Proc Natl Acad Sci USA.1998, 95, № 14, P.8292−8297.
- Kamijo T., Bodner S., van de Kamp E., Randle D. H., Sherr C. J. Tumor spectrum in ARF-6bma deficient mice. //Cancer Res. 1999, V.59, P.2217−2222.
- Kefford RF, Newton-Bishop JA, Bergman W, et al. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the Melanoma Genetics Consortium. // J Clin Oncol.1999, V.17, P.3245−51.
- Keller G, Vogelsang H, Becker I, et al. Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation.//Am J Pathol. 1999/V.155, № 2, P.337−42 .
- Kimonis VE, Goldstein AM, Pastakia B, et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome// Am J Med Genet. 1997, V.69, № 3, P.299−308.
- King M. Chromosomal rearrangements, speciation and the theoretical approach. //Heredity. 1987, V. l, P. 1−6.
- Kinzler KW, Vogelshtein B. Colorectal Cancer. //The Genetic Basis of Human Cancer. Ed. B. Vogelshtein and K. Kinzler /2nd Edition. 2002, P.583−642.
- Kinzler ICW, Nilbert MC, Su NKL. // Identification of FAP locus genes from chromosome 5q21. Science. 1991, V.253, P.661−664.
- Kleinerman RA, Tucker MA, Abramson DH, et al. Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. //J Natl Cancer Inst. 2007, V.99, № 1, P.24−31.
- Knudson AG. Epidemiology of genetically determined cancer. Ciba Found Symp. 1989, V.142, P.3−12.
- Knudson AG Jr, Strong LC. Mutation and cancer: a model for Wilms' tumor of the kidney. //J Natl Cancer Inst. 1972, V.48, № 2, P.313−24.
- Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. //Proc Natl Acad Sci USA. 1971, V.68, P.820−3.
- Konopka B, Paszko Z, Janiec-Jankowska A, Goluda M. Assessment of the quality and frequency of mutations occurrence in PTEN gene in endometrial carcinomas and hyperplasias.// Cancer Lett. 2002, V.178, P.43−51.
- Kopf F.W.Goldmann R.J.Revers J.K. et al Familial malignant melanoma //JAMA. 1986, V.256, P.1915−1919.
- Kousseff B.G. The genetics of malignant melanomas //Ann.Plast.Surg. 1992, V.28, № 1, P.11−13.
- Kouvaraki MA, Shapiro SE, Perrier ND, et al. RET proto-oncogene, a review and update of genotype-phenotype correlations in hereditary medullarythyroid cancer and associated endocrine tumors.//Thyroid. 2005, V.15, № 6, P.531−544.
- Krassenstein R, Sauter E, Dulaimi E, et al. Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. //Clin Cancer Res.2004,V.10, P.28−32
- Kroiss MM, Vogt TM, Schlegel J, et al. Microsatellite instability in malignant melanomas.//Acta Derm Venereol. 2001, V.81, P.242−5.
- Larson T., Sjogren T. A methodological, psychiatric and statistical study of large Swedish rural population //Acta psychiatrica at neurological scandinavica. 1954, V.89, P.44−47.
- Lea CS, Holly EA, Hartge P, Lee JS, et al. Reproductive risk factors for cutaneous melanoma in women: a case-control study //Am J Epidemiol. 2007, V.165, № 5, P.505−513.
- Lee WC, Balsara B, Liu Z, Jhanwar SC, Testa JR. Loss of heterozygosity analysis defines a critical region in chromosome lp22 commonly deleted in human malignant mesothelioma. //Cancer Res. 1996, V 56, P.4297−4301.
- Lee WH, Bookstein R, Hong F, Young LJ, Shew JY, Lee EY. Human retinoblastoma susceptibility gene: cloning, identification, and sequence Science. 1987, V.235, P.1394−9
- Lee S., Lee H., Kim J et al. Aberant CpG island hypermethylation along multistep hepatocarcinogenesis. //Am. J. Phathol. 2003., V.163, P.1371−1378.
- Lengauer C., Kinzler K., W., Vogelstein B. Genetic instability in human cancer. //Nature. 1998, V.396, P.643−949.
- Lerman M.I., Minna J.D. et al. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes.// Cancer Research. 2000, V.60, P.6116−6133
- Lesueur F, Stasrk M., Tocco T. et al.// Genetic Heterogeneity in Familial Nonmedullary Thyroid Carcinoma: Exclusion of Linkage to RET, MNG1 and TCO in 56 Families. //J of Clin. Endocrin. Metabolism. 1999, V.84, №.6, P.2157−2162.
- Levi F, Randimbison L, Te VC, La Vecchia C. Second primary cancers in patients with lung carcinoma. //Cancer. 1999, V.86, P. 186−90.
- Levi F, Randimbison L, Te VC, Rolland-Portal I, Franceschi S, La Vecchia C. Multiple primary cancers in the Vaud Cancer Registry, Switzerland, 1974−89.//Br J Cancer. 1993, V.67, № 2, P.391−5.
- Lewis C.M., Cler L.R., Bu D.W. et al., Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk.// Clin Cancer Res.2005, V. l 1, P.166−72.
- Li L, Liu F, Ross AH.// PTEN regulation of neural development and CNS stem cells. //J Cell Biochem. 2003, V.88, P.24−28.
- Licciardello JT, Spitz MR, Hong WK. Multiple primary cancer in patients with cancer of the head and neck: second cancer of the head and neck, esophagus, and lung. Int J Radiat Oncol Biol Phys 1989, V.17, P.467−76.
- Lips CJ, Landsvater RM, Hoppener JW, Geerdink RA, et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. //N Engl J Med. 1994, V.331, № 13, P.828−35.
- Lore f., Talidis F., Cairano G.Di., Ranieri A. Multiple endocrine neoplasia type 2 syndromes may be associated with renal malformations. //J Int. Med. 2001, V.250, P.37−42.
- Lucchina LC., Barnhill RL, Duke DM, et al. Familial cutaneous melanoma. //Melanoma Res. 1995, V.5, P.413−418.
- Lynch H T, Clark WH, Reimer RR, Greene M, et al. Origin of familial malignant melanomas from heritable melanocytic lesions: the B-K mole syndrome. //Arch Dermatol. 1978, V. l 14, P.723−728.
- Lynch HT, Fitzgibbons R Jr. Surgery, desmoid tumors, and familial adenomatous polyposis: case report and literature review.//Am J Gastroenterol. 1996, V.91, № 1, P.2598−601.
- Lynch HT, Frichot BC, Lynch JF. Familial atypical multiple mole-melanoma syndrome. //J Med Genet. 1978, V.15, P.352−356.
- Lynch HT, Greene MH, Clark WH, Tucker MA, et al. High risk of malignant melanoma in melanoma-prone families with dysplastic nevi.//Ann Intern Med. 1985, V.102, № 4, P.458−465.
- Machens A., Gimm O., Hinze R., et al. Genotype -Phenotype correlation in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. //J Clin. Endocrinol. Metab. 2001, V.86, P. l 104−1109.
- Maehama, T. and Dixon J.E. // The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-triphosphate.// J. Biol. Chem. 1998, V. 273, P.13 375−13 378.
- Malchoff CD, Malchoff DM. Familial nonmedullary thyroid carcinoma. //Cancer Control. 2006, V. l, № 2, P. 106−10.
- Malchoff C., Malchoff D. The Genetics of Hereditary Nonmedullary Thyroid Carcinoma//J of Clin Endocrin. and Metabolism. 2002, V.87, № 6, P.2455−59.
- Malchoff D, Sarfarazi M, Tendler B, et al. Familial papillary thyroid carcinoma is genetically distinct from familial adenomatous polyposis coli. //Thyroid. 1999, V.9, P.247−252.
- Marra G, Boland CR. Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives.//! Natl Cancer Inst. 1995, V.87, № 15, P.1114−1125.
- Marx S. J Multiple endocrine neoplasia type 1. In: Kinzler KW, ed.//The genetic basis of human cancer.- 2nd ed.NewYork.- McGraw Hill. 2002, P.475−500.
- Massi D, Sardi I, Urso C, et al. Microsatellite analysis in cutaneous malignant melanoma. //Melanoma Res. 2002, V.12, P.577−584.
- Matsuo K, Tang SH, Fagin JA.// Allelotype of human thyroid tumors: loss of chromosome 11 ql3 sequences in follicular neoplasms. //Mol Endocrinol., 1991, V.5,P.l 873−1879.
- McKay JD, Lesueur F, Jonard L, Pastore A, et al. Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. //Am J Hum Genet. 2001, V.69, P.440−446.
- Meellemkjaer L., Friis S., Olsen J.H., et al // Risk of cancer among women with breast cancer.// Int. J Cancer, 2006, V. l 18, № 9, P.2285−92.
- Merlo A., Herman J. G., Mao L., Lee D. J., et al. CpG island methylation is associated with transcriptional silencing of the tumor suppressor pl6/CDK2/ MTS1 in human cancers.//Nat. Med. 1995, V. l, P.686−692.
- Mulligan L.M., Eng C., Healey CS., Clayton D., KwookJ.B., Gardner E., Ponder M.A. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN2A and FMTC. //Nature Genet. 1994, V.7, P.70−74.
- Mulligan L.M., Kwok J.B., Healey C.S., Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2K. II Nature. 1993, V.363, P.458−460.
- Myers SM, Eng C, Ponder BA, Mulligan LM. Characterization of RET proto oncogene 3' splicing variants and polyadenylation sites: a novel C-terminus for RET// Oncogene. 1995, V. l 1, № 10, № 3, P.2039−2045.
- Nakamura T, Ishizaka Y, Nagao M, Hara M, Ishikawa T. Expression of the ret proto-oncogene product in human normal and neoplastic tissues of neural crest origin.// J Pathol. 1994, V. l72, №.3, P.255−60.
- Nakamura T. Genetic markers and animal models of neurocristopathy. //His-tol Histopathol. 1995, V.10, № 3, P.747−759.
- Nakamura M., Watanabe T., Klangby U., Asker C., Wiman K., Yonekawa Y., Kleihues P., Ohgaki H. pl4ARF deletion and methylation in genetic pathways to glioblastomas. //Brain Pathol. 2001, V. l 1, P.59−168
- Nelen M.R., PadbergG.W., Peeters E.A. at al. Localization of the gene for Cowden disease to chromosome 10q22−23.//Nat. Genet. 1996, V.13, P. 114−116.
- Nicolaides N., Papadopoulos N., Liu B. et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer .//Nature. 1994, V. 371, P.75−80.
- Nikiforov YE, Steward DL, Robinson-Smith TM, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. //J Clin Endocrinol Metab. 2009, V.94, № 6, P.2092−8.
- Nikiforova MN, Stringer JR, Blough R. et al. // Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. //Science. 2000, V.290, P.138−141.
- Nobori T., Miura K, Wu DJ, et al. Deletionsof the cyclin-dependent kinase-4 ingibitor gene in multiple human cancers. //Nature. 1994, V.368, P.753 -756.
- Oda S, Maehara Y, Sumiyoshi Y, Sugimachi K. Microsatellite instability in cancer: what problems remain unanswered? Surgery. 2002, V.31, P. 55−62.
- Pachnis V, Mankoo B, Costantini F // Expression of the c-ret proto-oncogene during mouse embryogenesis. //Development. 1993, V. l 19, P. 1005−1017.
- Pal T, Vogl FD, Chappuis PO, Tsang R, et al. Increased risk for nonmedul-lary thyroid cancer in the first degree relatives of prevalent cases of nonmedul-lary thyroid cancer: a hospital-based study. //J Clin Endocrinol. 2001, V.86, № 11, P.5307−5312.
- Papadopoulos N, Nicolaides NC, Liu B, et al. Mutations of GTBP in genetically unstable cells. //Science. 1995, V.268, № 5219, P. 1915−7.
- Pavel S, Smit NP. Metabolic interference of melanogenesis in pigment cells. //Sb Lek. 1996, V.97, № 13, P.29−39.
- Pearse AG, Polak JM. Endocrine tumours of neural crest origin: neurolopho-mas, apudomas and the APUD concept.// Med Biol. 1974 V52, № 1, P.3−18.
- Peris K, Keller G, Chimenti S, et al. Microsatellite instability and loss of heterozygosity in melanoma.//J Invest Dermatol 1995, V.105, P.625−628.
- Pitot HC. Animal models of neoplastic development //Dev Biol (Basel). 2001, V.106, P.53−7
- Plail RO, Bussey HJ, Glazer G, Thomson JP. Adenomatous polyposis: an association with carcinoma of the thyroid. //Br J Surg. 1987, V.74, № 5, P.377−80.
- Pollock PM, Walker GJ, Que Noy T, Bloch N, Hay ward NK. Loss of the PTEN gene is important for the propagation of melanoma cells in culture, but is infrequent in melanoma tumours. //Melanoma Res. 2002, V.12, P.565−575.
- Pomerantz J., Schreiber-Agus N., Liegeois N. J., et al. The INK4a tumor suppressor gene product, pl9Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. //Cell. 1998, V.92, P.713−723.
- Ponder BA, Ponder MA, Coffey R, et al. Risk estimation and screening in families of patients with medullary thyroid carcinoma. //Lancet. 1988, V. l, № 82, P.397−401.
- Protopopov A., Kashuba V., Zabarovska V.I., et al. An integrated physical and gene map of the 3.5-Mb chromosome 3p21.3 (AP20) region implicated in major human epithelial malignancies.//Cancer Res. 2003, V.63, P.404−412.
- Punales M.K., Graf H., Gross J.L., Maia A.L. RET Codon 634 Mutations in Multiple Endocrine Neoplasia Type 2: Variable Clinical Features and Clinical Outcome. //J Clin. Endocrinology.2002, V.88, P.2644−2649.
- Quelle, D. E, Cheng M., Ashmun R. A, Sherr C.J. Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by pl6/INK4a, but not by the alternative reading frame protein pl9/ARF. //Proc. Natl. Acad. Sci.1997, V.94, P.669−673.
- Quelle, D. E, Zindy F., Ashmun R.A., Sherr C.J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. //Cell. 1995, V.83, P.993−1000.
- Quinn AG, Healy E, Rehman I, et al. Microsatellite instability in human non-melanoma and melanoma skin cancer. J Invest Dermatol. 1995, V. 104, P.309−312.
- Raue F, Frank-Raue K. Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management. Hormones (Athens). 2009, V.8, № 1, P.23−28.
- Ranade K, Hussussian CJ, Sikorski RS, Varmus HE, Goldstein AM, Tucker MA, Serrano M, Hannon GJ, Beach D, Dracopoli N. Mutations associated with familial melanoma impair p 16INK4 function.//Nat. Genet. 1995, V.10, № 1, P.114−116.
- Regitnig P, Ploner F, Maderbacher M, Lax SF. Bilateral carcinomas of the breast with local recurrence- analysis of genetic relationship of the tumors.// Mod Pathol. 2004, V. l7, P.597−602.
- Reifenberger J., Wolter M., Bostrom J., et al. Allelic losses on chromosome arm lOq and mutation of the PTEN (MMAC 1) tumor supressor gene in primary and metastatic malignant melanomas. //Virchov Arch. 2000, № 436, P.487−493.
- Reynolds RM, Reynolds RM, Weir J, Stockton DL, Brewster DH, Sandeep TC, Strachan MW. Changing trends in incidence and mortality of thyroid cancer in Scotland.//Clin Endocrinol (Oxf). 2005, V.62, № 2, P. 156−62.
- Riccardi VM. The genetic predisposition to and histogenesis of neurofibromas and neurofibrosarcoma in neurofibromatosis type 1.// Neurosurg. Focus. 2007, V.22, № 6 :E3. Review.
- Richetta A, Ottini L, Falchetti M, et al. Instability at sequence repeats in melanocyte tumours. //Melanoma Res. 2001, V. l 1, P.283−289.
- Richetta A, Silipo V, Calvieri S, et al. Microsatellite instability in primary and metastatic melanoma.// J Invest Dermatol 1997, V.109, P. 119−20.
- Risinger JI, Berchuck A, Kohler MF, Boyd J. Mutations of the E-cadherin gene in human gynecologic cancers. //Nat Genet. 1994, V.7, P.98−102.
- Risch HA, McLaughlin JR, Cole DE, Rosen B, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.// J Nat Cancer Inst. 2006, V.98, № 23, P. 1675−7
- Roberts T, Chernova O, Cowell JK. Molecular characterization of the lp22 breakpoint region spanning the constitutional translocation breakpoint in a neuroblastoma patient with a t (l-10)(p22-q21). //Cancer Genet Cytogenet. 1998, V.100, P. 10−20.
- Robertson, G.P., Fumari F. B, Miele M.E., et al. In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. //Proc. Natl. Acad. Sci. 1998, V.95, P.9418−9423.
- Ron E, Kleinerman RA, Boice Jr D, LiVolsi VA, Flannery JT, Fraumeni Jr. A population-based case-control study of thyroid cancer. //J Natl. Cancer Inst. 1987, V.79, P.1−12.
- Ronckers CM, McCarron P, Ron E. Thyroid cancer and multiple primary tumors in the SEER cancer registries. // Int J Cancer. 2005, V. l 17, P.281−288.
- Rossel M, Schuffenecker I, Schlumberger M, et al. Detection of a germline mutation at codon 918 of the RET proto-oncogene in French MEN 2B famili-es.//Hum Genet. 1995, V.95, № 4, P.403−406.
- Rossel M, Pasini A, Chappuis S, Geneste O, Fournier L, Schuffenecker I, et al. Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations. // Oncogene. 1997, V.14, № 3, P.265−75.
- Rubben A, Bogdan I, Grussendorf-Conen EI, Burg G, Boni R. Loss of heterozygosity and microsatellite instability in acquired melanocytic nevi: towards a molecular definition of the dysplastic nevus. Recent Results //Cancer Res. 2002, V.160, P.100−10.
- Rubino C, de Vathaire F, Dottorini ME. et al. Second primary malignancies in thyroid cancer patients. //Br J Cancer. 2003, V.89, P. 16384.
- Rydzanicz M, Wierzbicka M, Gajecka M, et al. The impact of genetic factors on the incidence of multiple primary tumors (MPT) of the head and neck. //Cancer Lett. 2005, V.224, № 2, P.263−78.
- Samuels Y, Wang Z, Bardelli A, Silliman N at al. High frequency of mutations of the PIK3CA gene in human cancers. //Science. 2004, V.304, P.554−558.
- Sandberg T., Nilsson K., Johannsson O., et al. Frequency of Multiple Melanomas and Breast and Pancreas Carcinomas in CDKN2A Mutation-Positive Melanoma Families//J Natl. Cancer Inst. 2001, V. 92, № 15,P.1260−1266.
- Santoro M, Carlomagno F, Romano A, et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B.// Science.1995, V.267, № 5196, P.381−3.
- Sarantaus L, Vahteristo P, Bloom E, at al. BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients.//Eur J Hum Genet. 2001, V.9, P.424−30.
- Scelo G, Boffetta P, Corbex M, et al. Second primary cancers in patients with nasopharyngeal carcinoma: a pooled analysis of 13 cancer registries. //Cancer Causes Control. 2007, V. l 8, № 3, P.269−78.
- Schimke R.N. The Genetics of Human Cancer. Eds J. Mulvihill, R. Miller, J. Fraumeni Jr. //Chap.- New York, 1977, P. 179−198.
- Schreiber-Agus N, Meng Y, Hoang T, et al. Role of Mxil in ageing organ systems and the regulation of nonnal and neoplastic growth. //Nature. 1998, V.393, № 6684, P.483−7.
- Schuchardt A, D’Agati V, Larsson-Blomberg L, at al. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor RET. //Nature. 1994, Y.367, P.380−383.
- Serrano M, Gomez-Lahoz E, DePinho RA, et al. Inhibition of ras-induced prolixferation and cellular transformation by pl6INK4.//Science. 1995, V.267, P.249−52.
- Serrano M. The tumor suppressor protein pl6INK4a.// Exp Cell Res. 1997, V.23, № 1, P.7−13.
- Serrano M., Lee H., Chin L., et al. Role of the INK4a locus in tumor suppression and cell mortality. //Cell. 1996, V.85, P.27−37.
- Sherr C.J. Cancer cell cycles. //Science. 1996, V.274, P.1672−1676.
- Skender-Kalnenas N.M. English D.R., Heeman P.J. Benign melanocytic lesions: risk markers or precursors of melanoma? //J.Am. Acad. Dermatol. 1995, V.33, № 6, P.1000−1007.
- Skinner M.A., Jeffrey A., Moley M.D., at al. Prophylactic Thyroidectomy in Multiple Endocrine Neoplasia Type 2A. //N Engl J of Med. 2005, V.353, № 11, P.1105−1113.
- Skinner MA, Moley JA, Dilley WG, Owzar K, Debenedetti MK, Wells SA., Jr Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. // N Engl J Med. 2005, V.353, № 11, P. 1105−1113.
- Sokova 01, Kirichenko OP, Mukeria AF, Demidov LV, Chebotarev AN, Kopnin BP. Enhanced expression of lp32 and lp22 fragile sites in lymphocytes in cutaneous malignant melanomas. //Cancer Genet Cytogenet. 1992, V.58, P.24−28.
- Soravia C., Sugg S.L., Berk T., at all.// Familial adenomatous polyposis-as-sociated thyroid cancer.// Am J Pathol. 1999, Y.15, P. 127−135.
- Stoffer SS, Van Dyke DL, Bach JV, Szpunar W, Weiss L. Familial papillary carcinoma of the thyroid.//Am J Med Genet. 1986, V.25, № 4, P.775−82.
- Stratton MR, Ford D, Neuhasen S, Seal S, Wooster R, Friedman LS, King MC, Egilsson V, Devilee P, McManus R, et al. Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. //Nat Genet. 1994, № 1, P.103−7.
- Suarez HG, du Villard JA, Severino M, et al. Presence of mutations in all three ras genes in human thyroid tumors.//Oncogene.l 990, V.5,P.565−570.
- Suchy J., Kurzawski G., Jakubowska K at al. Frequency and Nature of MSH6 Gemline Mutation in Polish Patients with Colorectal, Endometrial and Ovarian Cancers.//Hereditary Cancer in Clinical Practice. 2006, V.4, № 1, P.60−5.
- Sugg SL, Zheng L, Rosen IB, Freeman JL, Ezzat S, Asa SL. ret/PTC-1, -2, and -3 oncogene rearrangements in human thyroid carcinomas: implications for metastatic potential?// J Clin Endocrinol Metab. 1996, V.81, P.3360−3365.
- Sutherland GR, Ledbetter DH. Report of the committee on cytogenetic markers //Cytogenet Cell Genet. 1989, V.51, № 1−4, P.452−458.
- Szinnai G., Meier C., Komminoth P., Zumsteg U. Review of Multiple Endocrine Neoplasia Type 2 A in Children: Therapeutic Result of Early Thyroidectomy and Prognostic Value of Codon Analysis. //Pediatrics. 2003, V. l 11,№ 2, P.132−139.
- Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers.// J Natl Cancer Inst. 2007, V.99, P. 1811 1814.
- Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. //Cell. 1985, V.42, № 2, P.581−588.
- Takahashi M. The GDNF/RET signaling pathway and human disease. //Cytokine Growth Factor Rev. 2001, V. 12, P.361−373.
- Takahashi M., Buma Y., Hiai H. Isolation of ret proto-oncogene cDNA with an amino-terminal signal sequence.//Oncogene.l989, № 6, P.805−806.
- Tallini G, Asa SLRET oncogene activation in papillary thyroid carcinoma. //Adv Anat Pathol. 2001, V.8, № 6, P.345−54.
- Talwalkar VR, Scheiner M, Hedges LK, et al. Microsatellite instability in malignant melanoma. //Cancer Genet Cytogenet. l998,V.104, P. l 11−114.
- Teppo L, Salminen E, Pukkala E. Risk of a new primary cancer among patients with lung cancer of different histological types. //Eur J Cancer. 200, V.37, № 5, P.613−619.
- Thomas NE. BRAF somatic mutations in malignant melanoma and melanocyte naevi.//Melanoma Res. 2006, V.16, № 2, P.97−103
- Thompson D, Easton DF- Breast Cancer Linkage Consortium. Cancer Incidence in BRCA1 mutation carriers: J Natl Cancer Inst. 2002, 94, № 18, P.1358−65.
- Tomizawa Y., Kohno T., Kondo H., Otsuka A. et al. Clinicopathological sig-nifycance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.//Clin. Cancer Res. 2002, V.8, P.2362−2368.
- Travis LB, Curtis RE, Boice JD Jr, Platz CE, Hankey BF, Fraumeni JF Jr. Second malignant neoplasms among long-term survivors of ovarian cancer. //Cancer Res., 1996, V.56, P.1564−70.
- Tripp JM, Kopf AW, Marghoob AA, Bart RS. Management of dysplastic nevi: a survey of fellows of the American Academy of Dermatology. //J Am Acad Dermatol. 2002, V.46, P.674−682.
- Tsao H, Sober AJ. Ultraviolet radiation and malignant melanoma.//Clin Dermatol. 1998, V.16, P.67−73.
- Tucker MA, Halpern A, Holly EA et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma.// JAMA. 1997, V.277, P. 1439−1444.
- Turleau C, De Grouchy J. Constitutional karyotypes in retinoblastoma. //Ophthalmic Paediatr Genet. 1987, V.8, № 1, P. 11−17.
- Uchino S, Noguchi S, Kawamoto H, Yamashita H, Watanabe S, Yamashita H, Shuto S. Familial nonmedullary thyroid carcinoma characterized by multifo-cality and a high recurrence rate in a large study population.// World J Surg. 2002, V.26, № 8, P.897−902.
- Vazina A, Baniel J, Yaacobi Y, Shtriker A, Engelstein D, Leibovitz I, et al. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel //Br J Cancer. 2000, V.83, P.463−6.
- Venkitaraman A.R. Cancer susceptibility and the functions of BRCA1 and BRCA2. //Cell. 2002, V.108, P.171−182.
- Verma et al Verma M, Dunn BK, Ross S et al. Early detection and risk assessment: proceedings and recommendations from the Workshop on Epigene-tics in Cancer Prevention. Ann N Y //Acad Sci. 2003, V.983, P. 298−19.
- Vlahovic G, Crawford J. Activation of tyrosine kinases in cancer. //Oncologist. 2003, V.8,№ 6,P.531−8.
- Walker JG, Palmer JM, Walter MK. A genetic model of melanoma tumori-genesis based on allelic losses.// Genes Chromosomes Cancer. 1995, V.12, P.134−41.
- Wassberg C, Thorn M, Yuen J, Ringborg U, Hakulinen T. Second primary cancers in patients with squamous cell carcinoma of the skin: a population-based study in Sweden.//Int J Cancer. 1999, V.80, P.511−515.
- Watanabe T., Nakamura M., Yonekawa Y., et al. H. Promoter hyperme-thylation and homozygous deletion of the pl4ARF and pl6INK4a genes in oligodendrogliomas. //ActaNeuropathol. 2001, V.101, P.185−189.
- Wells SA, Gosnell JE, Gagel RF, et al. Vandetanib in metastatic hereditary medullary thyroid cancer: Follow-up results of an open-label phase II trial. ASCO Annual Meeting Proceedings Part 1. J Clin Oncol. 2007, V.25 (18S).
- Willem J., de Groot В., Links T.P., Plukker J T., et al. RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors //Endocrine Reviews. 2006, V.27, № 5, P.535−56.
- Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13ql2−13. //Science. 1994, V.265, № 5181, P.2088−90.
- Wong SS, Lozano G, Gaff CL, Gardner RJ, et al/Novel p53 germline mutation in a patient with Li-Fraumeni syndrome.// Intern Med J. 2003, V.33, № 12, P.621−623.
- Yamamoto M, Taguchi K, Baba H, et al. Loss of protein expression of hMLHl and hMSH2 with double primary carcinomas of the stomach and colo-rectum. //Oncology Reports. 2006, V.16, № 1, P.41−47.
- Yamamoto S. Y, Yoshimura K., Ri S., et al. The risk of Multiple Primary Malignancies with Colorectal Carcinoma//Dis.Colon and Rectum. 2006, V. 19, P.830−836.
- Yoshida K., Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage.//Cancer Sci. 2004, V.95, P.866−871.
- You YN, Lakhani V, Wells SA, et al. New directions in the treatment of thyroid cancer. //J Am Coll Surg. 2007, V.205, № 4, (Suppl), P.45−48.
- Zedenius J, Wallin G, Svensson A, et al. //Allelotyping of follicular thyroid tumors. //Hum Genet. 1995, V.96, P.27−32.
- Zhang J, Glatfelter AA, Taetle R, Trent JM. Frequent alterations of evolutio narily conserved regions of chromosome 1 in human malignant melanoma. //Cancer Genet Cytogenet. 1999, V. lll, P.119−23.